Vantia Therapeutics Mailing List

You can subscribe to our mailing list using this form - please fill in all the fields. We will use the mailing list to inform you of Vantia Therapeutics news and information. We will not pass your details to third parties.

Vantia Therapeutics Mailing List
News

VA106483 Phase IIb trial for nocturia

2 February 2010

Vantia Therapeutics' lead candidate VA106483 enters Phase IIb trial for nocturia more »

VA111913 Phase II trial in dysmenorrhoea

6 October 2009

Vantia Therapeutics' lead candidate VA111913 enters Phase II POC trial in dysmenorrhoea more »

Vantia Therapeutics is an emerging pharmaceutical company developing novel, small molecule drugs targetting large, under-served medical markets.

Its rapidly advancing clinical pipeline includes VA106483 for nocturia and VA111913 for dysmenorrhoea, product candidates that target conditions affecting millions of people, are poorly treated and represent billion dollar markets.

Vantia Therapeutics was spun out from Ferring Research Ltd in 2008. The product pipeline is driven by its small molecule drug discovery and development capabilities and Vantia Therapeutics' experienced management team.

Vantia Therapeutics' strategy is to develop candidates to Phase II proof-of-concept and then commercialise them through partnerships.

The Company is well funded and backed by specialist life science investors MVM Life Science Partners, SV Life Sciences and Novo A/S.